To investigate the therapeutic effects of the MACC1-AS1/STK33 axis on pancreatic cancer resistance, the chemotherapeutic response of resistant animals to gemcitabine after stable overexpression of MACC1-AS1 was examined (Fig. 7A–D). This evidence concerns the gene MACC1 and pancreatic neoplasm.